Novel agents for advanced pancreatic cancer

被引：28
作者：
Akinleye, Akintunde [1 ]
Iragavarapu, Chaitanya [1 ]
Furqan, Muhammad [2 ]
Cang, Shundong [3 ]
Liu, Delong [4 ,5 ]
机构：
[1] New York Med Coll, Dept Med, Div Hematol Oncol, Valhalla, NY 10595 USA
[2] Univ Iowa, Dept Med, Div Hematol Oncol, Iowa City, IA 52242 USA
[3] Zhengzhou Univ, Henan Prov Peoples Hosp, Dept Oncol, Zhengzhou 450052, Peoples R China
[4] Zhengzhou Univ, Henan Canc Hosp, Dept Oncol, Zhengzhou 450052, Peoples R China
[5] Zhengzhou Univ, Affiliated Canc Hosp, Zhengzhou 450052, Peoples R China
来源：
ONCOTARGET | 2015年 / 6卷 / 37期
关键词：
pancreatic cancer; IGF-IR; PHASE-III TRIAL; FACTOR-I RECEPTOR; HUMANIZED MONOCLONAL-ANTIBODY; STEM-CELL ANTIGEN; GEMCITABINE PLUS PLACEBO; HEDGEHOG SIGNALING PATHWAY; GROWTH-FACTOR RECEPTOR; INHIBITS TUMOR-GROWTH; ANTITUMOR-ACTIVITY; COMPARING GEMCITABINE;
D O I：
10.18632/oncotarget.3999
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Pancreatic cancer is relatively insensitive to conventional chemotherapy. Therefore, novel agents targeting dysregulated pathways (MAPK/ERK, EGFR, TGF-beta, HEDGEHOG, NOTCH, IGF, PARP, PI3K/AKT, RAS, and Src) are being explored in clinical trials as monotherapy or in combination with cytotoxic chemotherapy. This review summarizes the most recent advances with the targeted therapies in the treatment of patients with advanced pancreatic cancer.
引用
收藏
页码：39521 / 39537
页数：17
相关论文
共 147 条
  • [11] [Anonymous], 18 EORTC NCI AACR S
  • [12] [Anonymous], ANN ONCOLOGY
  • [13] [Anonymous], J CLIN ONCOL
  • [14] [Anonymous], J CLIN ONCOL
  • [15] [Anonymous], 1027082 F HOFFM LTD
  • [16] [Anonymous], PHASE 1 1 MAN STUDY
  • [17] [Anonymous], 2010 GASTR CANC S
  • [18] [Anonymous], ANN ONCOLOGY
  • [19] [Anonymous], J CLIN ONCOL
  • [20] Phase I rapid dose-escalation study of AGS-1C4D4, a human anti-PSCA (prostate stem cell antigen) monoclonal antibody, in patients with castration-resistant prostate cancer: a PCCTC trial
    Antonarakis, Emmanuel S.
    Carducci, Michael A.
    Eisenberger, Mario A.
    Denmeade, Samuel R.
    Slovin, Susan F.
    Jelaca-Maxwell, Kathy
    Vincent, Martha E.
    Scher, Howard I.
    Morris, Michael J.
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2012, 69 (03) : 763 - 771
12345678910